Latest news

We are delighted to invite our members to submit suggestions for the next PVRI Digital series, which is scheduled to start in September 2025 and will run for 18 months.

Rubin Tuder, a trailblazer in the field of pulmonary vascular biology and a driving force in PH research, has been honoured with the PVRI Lifetime Achievement Award for 2025. This prestigious Award is given annually at the PVRI Annual Congress to a senior PH investigator or clinician for their exceptional and outstanding contributions to the field of pulmonary vascular disease and to PVRI. This recognition celebrates his unparalleled contributions to science, mentorship, and the global PH community. 

The Burke Advanced Fellowship in Pulmonary Heart Disease at The Brigham and Women’s Hospital and Harvard Medical School—invites applications for an advanced fellowship in pulmonary heart disease starting July 1, 2026. This training program is sponsored by the Center for Pulmonary Heart Disease at the Brigham and Women’s Hospital. The position offers an intensive clinical experience including evaluation and management of both inpatients and outpatients with pulmonary vascular disease and right heart dysfunction or failure. In addition, applicants are strongly encouraged to participate in a translational or clinical research program.

We are excited to announce that registration is open for the PVRI Drug Discovery and Development Symposium 2025! #DDDS2025 will be taking place 16-17 June 2025 in Amsterdam and promises to be an excellent opportunity for regulatory, industry, and academic bodies to meet and discuss the latest drug developments in PH.

Hot topics from PVRI GoDeep, led by Werner Seeger, is a session in the PVRI 2025 programme and will take place on Saturday, 1 February 2025. Presentations include: Overview of the GoDeep meta-registry; Risk scores beyond group 1 PH – baseline and follow-up; Survival outcomes and impact of targeted PAH therapy in PoPH; PAH-targeted therapies in group 3 PH – PDE5 inhibitor therapy associated with improved survival; Male survival disadvantage in PH: independent of etiology, age, disease severity, comorbidities and treatment, but race-dependent

On 27 September 2024, phase 1 of the Pulmonary Hypertension Global Patient Survey (PH GPS) closed. The survey was first launched in October 2023 to help clinicians better understand the impacts of PH on patients.

This World Heart Day, PVRI supports the WHF campaign calling for increased awareness, better healthcare policies and more funding for heart health research. 

The PVRI launched the Pulmonary Hypertension Global Patient Survey (PH GPS) in October 2023 to help clinicians better understand the impacts of PH on patients. The first global survey of its kind was aimed at those living with PH and their carers. 

The Aristotle Classes on PH & ACHD is a scientific event organised jointly by the Medical School of Aristotle University, Thessaloniki, Greece, the Heart Center at the University of Cologne, Germany and Royal Brompton & Harefield Hospitals, Imperial College, London, UK.